PREVNAR 13 2.2 MCG / 0.5 ML — DIN 02335204
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4.4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 34 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2.2 MCG / 0.5 ML · PFIZER CANADA ULC · SUSPENSION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is PREVNAR 13?
PREVNAR 13 2.2 MCG / 0.5 ML contains PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4.4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 34 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2.2 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02335204, held by PFIZER CANADA ULC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 14-May-2026. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is PREVNAR 13 used for?
Active immunization for prevention of invasive pneumococcal disease and pneumonia caused by 13 S. pneumoniae serotypes in infants, children, and adults 18 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Pneumococcus, Purified Polysacc.antigen Conjugated cost around the world?
Pneumococcus, Purified Polysacc.antigen Conjugated is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory); Luxembourg publishes a reimbursement. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 4 | 5 | CZK███.██ |
| United Arab Emirates | public | 2 | 3 | AED███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
14 pack listings across 12 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Pneumococcus, Purified Polysacc.antigen Conjugated pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Pneumococcus, Purified Polysacc.antigen Conjugated in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Pneumococcus, Purified Polysacc.antigen Conjugated, across 10 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MERCK CANADA INC | 4 | 2 | CAPVAXIVE, PNEUMOVAX 23, PNEUMOVAX 23 -(5-DOSE), VAXNEUVANCE | Sourceable in Canada |
| PFIZER CANADA ULC | 3 | 1 | PREVNAR, PREVNAR 13, PREVNAR 20 | Sourceable in Canada |
| GLAXOSMITHKLINE INC | 1 | 0 | SYNFLORIX | No marketed DIN |
| LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | 1 | 0 | PNU-IMUNE 23 | No marketed DIN |
| SANOFI PASTEUR LIMITED | 1 | 0 | PNEUMO 23 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.2 MCG / 0.5 ML |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | Single-dose, 0.5 mL pre-filled syringe. Pack sizes of 1 and 10, without needles. Tip cap and rubber plunger are latex-free. |
| Storage | Store at 2 to 8°C. Do not freeze. Discard if vaccine has been frozen. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Pneumococcus, Purified Polysacc.antigen Conjugated |
|---|---|
| ATC code | J07AL02 |
| AHFS class | 80:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02335204 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2335204 |
| Brand name | PREVNAR 13 |
| Generic / active ingredient | PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4.4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 34 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2.2 MCG / 0.5 ML |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Schedule D |
| ATC code | J07AL02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07AL |
| Current status | CANCELLED POST MARKET |
| Status date | 14-May-2026 |
| Original market date | 2010-03-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Single 0.5 mL IM dose. Infants: 3-dose primary series (2, 4, 6 months) plus booster at 12-15 months. HSCT: 4-dose series. Preferred sites: anterolateral thigh (infants) or deltoid (older children/adults).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the vaccine, including diphtheria toxoid or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Postpone in acute severe febrile illness. Caution in individuals with coagulation disorders. Immunocompromised may have reduced response. Does not protect against non-vaccine serotypes.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAPVAXIVE | 4 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | MARKETED | 02549891 |
| PREVNAR 20 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | MARKETED | 02527049 |
| VAXNEUVANCE | 30 MCG / 0.5 ML | SUSPENSION | MERCK CANADA INC | MARKETED | 02522403 |
| PNEUMO 23 | 25 MCG / 0.5 ML | LIQUID | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | 02231259 |
| PNEUMOVAX 23 | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | 00431648 |
| PNEUMOVAX 23 -(5-DOSE) | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | 02240632 |
| PNU-IMUNE 23 | 25 MCG / 0.5 ML | LIQUID | LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | CANCELLED POST MARKET | 02230175 |
| PREVNAR | 20 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02244081 |
| SYNFLORIX | 3 MCG / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | 02320541 |
2 · Same class — other molecules in ATC J07AL
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pneumococcus, Purified Polysacc.antigen Conjugated | CAPVAXIVE · PNEUMO 23 · PNEUMOVAX 23 · PNEUMOVAX 23 -(5-DOSE) · +6 more | 10 | 3 | Yes |
| Pneumococcus, Purified Polysaccharides Antigen | PNEUMOVAX 23 | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07AH | Meningococcal Vaccines · Meningococcus B, Multicomponent Vaccine · Meningococcus C, Purified Polysaccharides Antigen Conjugated · Meningococcus, A, C, Bivalent Purified Polysacc. Antigen · Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen · +1 more | 17 | 6 |
| J07AE | Cholera, Inactivated, Whole Cell · Cholera, Live Attenuated | 4 | 2 |
| J07AP | Typhoid, Inactivated, Whole Cell · Typhoid, Oral, Live Attenuated · Typhoid, Purified Polysaccharide Antigen | 5 | 2 |
| J07AM | Tetanus Toxoid · Tetanus Toxoid, Comb. With Diphtheria Toxoid | 7 | 1 |
| J07AX | Other Bacterial Vaccines | 4 | 1 |
| J07AG | Hemophilus Influenzae B Vaccines · Hemophilus Influenzae B, Combinations With Pertussis And Toxoids · Hemophilus Influenzae B, Combinations With Toxoids · Hemophilus Influenzae B, Purified Antig. Conjugated | 8 | 1 |
| J07AJ | Pertussis, Inact., Whole Cell, Comb. With Toxoids · Pertussis, Inactivated, Whole Cell · Pertussis, Purified Antigen · Pertussis, Purified Antigen, Comb. With Toxoids | 7 | 1 |
| J07AN | Tuberculosis, Live Attenuated | 2 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADACEL | PERTUSSIS TOXOID : 2.5 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 5 MCG / 0.5 ML DIPHTHERIA TOXOID : 2 LF / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML TETANUS TOXOID : 5 LF / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02240255 |
| DUKORAL | VIBRIO CHOLERAE INABA 48 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE INABA 6973 EL TOR BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS RECOMBINANT CHOLERA TOXIN B SUBUNIT : 1 MG | VALNEVA SWEDEN AB | MARKETED | 02247208 |
| VAXCHORA | VIBRIO CHOLERAE, STRAIN CVD 103-HGR, LIVE : 2000000000 UNIT | BAVARIAN NORDIC AS | MARKETED | 02538164 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PREVNAR 13 called?
The same molecule, Pneumococcus, Purified Polysacc.antigen Conjugated, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| VAXNEUVANCE | Latin | Czechia |
| CAPVAXIVE | Latin | Czechia |
| VAXNEUVANCE™ | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.